Zymeworks Presents New Phase 1 Data for ZW191 at ESMO
Zymeworks presented new Phase 1 data for its folate receptor alpha-targeting antibody-drug conjugate ZW191 at the ESMO Congress 2026.
Zymeworks presented new Phase 1 data for its folate receptor alpha-targeting antibody-drug conjugate ZW191 at the ESMO Congress 2026.